Alle afleveringen
494 afleveringen, van nieuw naar oud
-
Vicore Pharma is leveraging in understanding the Renin-Angiotensin System (RAS) to develop angiotensin II type 2 receptor agonists for IPF and beyond
11 november 2025 · 7 min
CEO Ahmed Mousa walks us through the sciences and describes how data stacked up against a synthetic external control that was presented at a medical meeting this summer.
-
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
11 november 2025 · 10 min
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs.
-
Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss
11 november 2025 · 9 min
Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.
-
Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
11 november 2025 · 13 min
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne.
-
Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
11 november 2025 · 8 min
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile.
-
Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins
10 november 2025 · 11 min
Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.
-
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
8 november 2025 · 10 min
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class. Lees meer
-
Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
8 november 2025 · 9 min
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
-
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
8 november 2025 · 12 min
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP. Lees meer
-
Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
8 november 2025 · 13 min
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study. Lees meer
-
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
8 november 2025 · 9 min
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
-
Brain shuttle technologies have been in the news a lot lately. Natalie Ricciardi explains what you need to know about 1st and 2nd generation technologies in development.
8 november 2025 · 8 min
She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.
-
Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways
5 november 2025 · 14 min
Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted. Lees meer
-
BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field
4 november 2025 · 8 min
CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.
-
BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes
4 november 2025 · 8 min
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.
-
BIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac
4 november 2025 · 8 min
CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.
-
BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science
4 november 2025 · 7 min
He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.
-
BIO-Europe 2025: Barcelona based Connecta Therapeutics is moving its neuroplasticity modulator for fragile X syndrome into a phase 2a study after completing first in human studies late last year
4 november 2025 · 11 min
CEO Jordi Fàbrega and CFO Josep Prous discusses the asset, CTH120, which is a NCE and proprietary to Connecta.
-
BIO-Europe 2025: Switzerland based ReproNovo is focused on reproductive health - with two clinical stage assets and three indications it is going after
3 november 2025 · 10 min
CEO Jean Marie Duvall describes the company's programs, one focused on male inferitliy and another that may have dual purposes of helping with embryo implantation and adenomyosis. She says to make sure there is a clear commercial path if when you focus on this field. Lees meer
-
BIO-Europe 2025: Anavo Therapeutics is focused on phosphatases - and is publicly talking about its two lead programs for the first time
3 november 2025 · 11 min
CEO Birgit Zech and CSO Edward Holson discuss the unique beginning of the company (a powerpoint deck), and the difficulties in drugging phosphatases. Plus, the company is now disclosing two indications/targets in development.
-
BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF
3 november 2025 · 10 min
CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.
-
BIO-Europe 2025: Valneva's partner Pfizer has been running a big trial of a Lyme disease vaccine that has covered the last three seasons - it will read out in the first part of next year
3 november 2025 · 17 min
Valneva CEO Thomas Lingelbach walks us through this program by describing how the vaccine is designed and how the study has been conducted. Plus, his comments on FDA's rescinding of the company's Chikungunya virus vaccine.
-
Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases
3 november 2025 · 16 min
Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work. Lees meer
-
BIO-Europe 2025: ReNewVax CEO Neil Murray believes the antigens the company has found will enable it to develop a pneumococcal vaccine that targets all ca.100 existing variants
3 november 2025 · 10 min
He describes the unmet need for a better vaccine than those already on the market, and says he is looking for a lead investor for a series A at BIO-Europe.
-
BIO-Europe 2025: Abivax CEO Marc de Garidel discusses physician and payor feedback after obefazimod's phase 3 UC induction readouts, and next steps regarding maintenance and Crohn's
3 november 2025 · 13 min
He describes the mechanism of the therapy, as well the data and commercial landscape for UC. Plus, how he thinks about combos and business development.
-
BIO-Europe 2025: AAVantgarde Bio, which is working on gene therapies for inherited retinal diseases that are caused by mutations in large genes, closed a $141M series B raise today
3 november 2025 · 11 min
CEO Natalia Misciattelli describes the lead programs for Stargardt Disease and Usher 1B Syndrome, and how AAVantgarde is able to solve the problem of delivering genes that are naturally too large for single AAV vectors.
-
Mathai Mammen recaps the first clinical data Parabilis Medicines reported on its beta-catenin program earlier this month at EMSO and AACR-NCI-EORTC 2025. Plus, degraders for prostate cancer, and more.
31 oktober 2025 · 24 min
He explains the company's "Helicon" peptide platform, and why he believes it is well suited to target previously undruggable problems like beta-catenin. Then he discusses clinical presentations on this program in multiple tumor types, and preclinical data on two degrader programs for prostate cancer. Lees meer
-
BiotechTV visited South San Francisco based Noetik and saw how they are digitizing tumor samples and using AI to sort through the complexity of the biology for drug discovery
30 oktober 2025 · 13 min
Co-Founder and CEO Ron Alfa walked BiotechTV's Ryan Flinn through how machine learning is taking cancer cell biology beyond the microscope.
-
Sonoma Biotherapeutics announced early clinical data today in a late-breaker at #ACR25 for its CAR-Treg to treat rheumatoid arthritis. Co-Founders Jeff Bluestone and Fred Ramsdell walk us through it.
30 oktober 2025 · 23 min
They explain why they believe a Treg based cell therapy is the right approach for autoimmune conditions, and describe the construct of this particular product. After discussing the data, they also comment on what they believe the big picture is for these types of Treg based treatments going forward. Lees meer
-
Zag Bio launched today with $80M, and aims to tackle autoimmune disease by using antibodies to reprogram how Tregs and Teffs are created in the thymus. The lead indication will be Type 1 diabetes
28 oktober 2025 · 10 min
CEO Jason Cole walks us through this unique science, which is based on work that co-founder Diane Mathis and colleagues published in Cell in 2022. The T1D program is scheduled to be in the clinic by late 2026.
-
Hemab Therapeutics, a company specializing in developing treatments for bleeding disorders, announced a $157 million series C raise today. CEO Benny Sorensen describes the work and unmet need.
27 oktober 2025 · 11 min
The company's lead program, a bi-specific called Sutacimig, has already reported phase 2 data for Glanzmann Thrombasthenia, and will start a pivotal in 2026. Hemab also has a monovalent antibody (HMB-022) in the clinic for the world's most common bleeding disorder, Von Willebrand Disease, and will be announcing an additional candidate next year. Lees meer
-
Weave Bio, which raised a $20M series A this month, is aiming to use software and LLMs to automate and streamline regulatory submissions for drug development
24 oktober 2025 · 9 min
Co-Founder & CEO Brandon Rice says that in one project it worked on with a pharma, Weave's technology took only 3 hours to draft regulatory documents what would have taken humans to 100 hours.
-
Ahead of a year of increased clinical activity, Entrada Therapeutics' CEO Dipal Doshi discusses the company's EEV platform, DMD programs, and a Vertex partnership in DM1
23 oktober 2025 · 21 min
He walks us through exon 44 and 45 programs, which will both likely have clinical readouts in 2026. Meanwhile, a $350M cash position gives Entrada the ability to think beyond neuromuscular conditions in the future as well.
-
Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
22 oktober 2025 · 23 min
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
-
Biotech entrepreneurs share advice on navigating through today's uncertain times: "It's going to be okay"
22 oktober 2025 · 52 min
MassBio CEO Kendalle Burlin O'Connell moderates a discussion with Normunity CEO Rachel Humphrey and Gallop Oncology CEO Luba Greenwood about how they are rising to today's challenges. Topics include the funding environment, motivating your team, storytelling, FDA Engagement, and perseverance. Lees meer
-
Flagship Pioneering announced its newest company to emerge out of stealth mode today: Expedition Medicines. It is leveraging generative design for small molecule covalent chemistry
22 oktober 2025 · 10 min
Co-Founder and CEO Molly Gibson explains the science behind the new company and the technology and equipment it uses for the work. Expedition has been funded with $50 million, and is also announcing a multi-target deal with Pfizer for prostate cancer. Lees meer
-
Biotech veteran Oz Azam has become the CEO of Cue Biopharma. He walks us through the science behind the company's new focus in autoimmune that has him excited about the opportunity
21 oktober 2025 · 15 min
He describes CUE-401, which combines a TGF-beta breathing-mask moiety with an interleukin (IL-2) mutein, and CUE-501, a Boehringer Ingelheim partnered program which is designed to deplete B-cells by painting them and engaging with virus-specific memory T-cells. Lees meer
-
Get to know Women In Bio, and how this organization helps women at all stages of their careers in biotech
21 oktober 2025 · 15 min
During a meeting in Boston at Portal Innovations where Women in Bio (WIB) was working on its 'Boardroom Ready' initiative, Dianne Keen-Kim (National President and Board Chair), Gina Ford (CEO), and Katherine Andersen (Board Member) discuss how WIB helps women in our industry today and its goals for the future. Lees meer
-
Emeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time
16 oktober 2025 · 21 min
Chairman & CEO Ben Hwang describes the idea behind Profusa's approach, and how he believes it delivers more robust and actionable information than purely surface based tools such as the Apple Watch.
-
PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose
15 oktober 2025 · 25 min
He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explain how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function. Lees meer
-
Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today
15 oktober 2025 · 8 min
The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community. Lees meer
-
Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
14 oktober 2025 · 8 min
He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development.
-
Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D
14 oktober 2025 · 5 min
He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D.
-
Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year
14 oktober 2025 · 10 min
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data. Lees meer
-
Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely
10 oktober 2025 · 13 min
Co-Founder & CEO Laurent Martinot discusses the raise, and the need for more accessible sleep health care. Plus, previewing a clinical trial of its device that will read out shortly.
-
Oxford's OrganOx became one of the UK's biggest news stories when it was announced it would be acquired by Japan's Terumo for approximately $1.5 billion - here's the revolutionary technology behind it
10 oktober 2025 · 17 min
CEO Craig Marshall describes how the company's "metra" device pumps blood through donor organs (currently livers) in order to extend the amount of time they can be transplanted safely.
-
Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBF
9 oktober 2025 · 13 min
CEO Ros Deegan discusses the deal and the path to getting there, and she highlights some of OMass' other programs the company is driving forward alone, including an MC2 antagonist. Plus, the company's unique expertise in the use of mass spec.
-
NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector
9 oktober 2025 · 7 min
He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates, employment, and other factors are affecting the broader economy, and might impact biotech.
-
Immuneering's CEO walks us through the company's MEK data in pancreatic cancer, and explains the science behind 'deep cyclic inhibition'
9 oktober 2025 · 23 min
Ben Zeskind describes the company's 9 month follow-up for atebimetinib + mGnP, which showed 86% overall survival and 53% progression free survival.
-
R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech
9 oktober 2025 · 41 min
He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more.